JP2011524858A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011524858A5 JP2011524858A5 JP2011509761A JP2011509761A JP2011524858A5 JP 2011524858 A5 JP2011524858 A5 JP 2011524858A5 JP 2011509761 A JP2011509761 A JP 2011509761A JP 2011509761 A JP2011509761 A JP 2011509761A JP 2011524858 A5 JP2011524858 A5 JP 2011524858A5
- Authority
- JP
- Japan
- Prior art keywords
- psgl
- binding
- human
- selectin
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108010054395 P-selectin ligand protein Proteins 0.000 claims 32
- 239000012634 fragment Substances 0.000 claims 29
- 102100034925 P-selectin glycoprotein ligand 1 Human genes 0.000 claims 21
- 210000000265 leukocyte Anatomy 0.000 claims 14
- 210000004698 lymphocyte Anatomy 0.000 claims 14
- 238000000034 method Methods 0.000 claims 13
- 210000002889 endothelial cell Anatomy 0.000 claims 12
- 108010092694 L-Selectin Proteins 0.000 claims 9
- 102000016551 L-selectin Human genes 0.000 claims 9
- 150000001875 compounds Chemical class 0.000 claims 8
- 238000012360 testing method Methods 0.000 claims 7
- 102100021942 C-C motif chemokine 28 Human genes 0.000 claims 6
- 102000019034 Chemokines Human genes 0.000 claims 6
- 108010012236 Chemokines Proteins 0.000 claims 6
- 101000897477 Homo sapiens C-C motif chemokine 28 Proteins 0.000 claims 6
- 125000003275 alpha amino acid group Chemical group 0.000 claims 6
- 230000009977 dual effect Effects 0.000 claims 6
- 102100021936 C-C motif chemokine 27 Human genes 0.000 claims 4
- 108010082161 Chemokine CCL19 Proteins 0.000 claims 4
- 102000003805 Chemokine CCL19 Human genes 0.000 claims 4
- 102000009109 Fc receptors Human genes 0.000 claims 4
- 108010087819 Fc receptors Proteins 0.000 claims 4
- 101000897494 Homo sapiens C-C motif chemokine 27 Proteins 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 229920001184 polypeptide Polymers 0.000 claims 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims 4
- 108010083702 Chemokine CCL21 Proteins 0.000 claims 3
- 102000006435 Chemokine CCL21 Human genes 0.000 claims 3
- 108010083675 Chemokine CCL27 Proteins 0.000 claims 3
- 102000006387 Chemokine CCL27 Human genes 0.000 claims 3
- 108010035766 P-Selectin Proteins 0.000 claims 3
- 102100023472 P-selectin Human genes 0.000 claims 3
- 239000000427 antigen Substances 0.000 claims 3
- 102000036639 antigens Human genes 0.000 claims 3
- 108091007433 antigens Proteins 0.000 claims 3
- 230000024203 complement activation Effects 0.000 claims 3
- 230000000295 complement effect Effects 0.000 claims 3
- 239000012636 effector Substances 0.000 claims 3
- 108020001507 fusion proteins Proteins 0.000 claims 3
- 102000037865 fusion proteins Human genes 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 230000005012 migration Effects 0.000 claims 3
- 238000013508 migration Methods 0.000 claims 3
- 230000037361 pathway Effects 0.000 claims 3
- 102000004169 proteins and genes Human genes 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 102100036846 C-C motif chemokine 21 Human genes 0.000 claims 2
- 101000713106 Homo sapiens C-C motif chemokine 19 Proteins 0.000 claims 2
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 claims 2
- 230000004968 inflammatory condition Effects 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 1
- 206010061430 Arthritis allergic Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000034189 Sclerosis Diseases 0.000 claims 1
- 102000003800 Selectins Human genes 0.000 claims 1
- 108090000184 Selectins Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 206010052779 Transplant rejections Diseases 0.000 claims 1
- 239000000853 adhesive Substances 0.000 claims 1
- 230000001070 adhesive effect Effects 0.000 claims 1
- 208000030961 allergic reaction Diseases 0.000 claims 1
- 230000036783 anaphylactic response Effects 0.000 claims 1
- 208000003455 anaphylaxis Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 230000001588 bifunctional effect Effects 0.000 claims 1
- 230000021164 cell adhesion Effects 0.000 claims 1
- 230000034196 cell chemotaxis Effects 0.000 claims 1
- 230000003399 chemotactic effect Effects 0.000 claims 1
- 230000035605 chemotaxis Effects 0.000 claims 1
- 230000008878 coupling Effects 0.000 claims 1
- 238000010168 coupling process Methods 0.000 claims 1
- 238000005859 coupling reaction Methods 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 238000011156 evaluation Methods 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 206010025135 lupus erythematosus Diseases 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- AAEVYOVXGOFMJO-UHFFFAOYSA-N prometryn Chemical compound CSC1=NC(NC(C)C)=NC(NC(C)C)=N1 AAEVYOVXGOFMJO-UHFFFAOYSA-N 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 238000012216 screening Methods 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 239000003981 vehicle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12779108P | 2008-05-15 | 2008-05-15 | |
| US61/127,791 | 2008-05-15 | ||
| PCT/US2009/044188 WO2009140623A2 (en) | 2008-05-15 | 2009-05-15 | Anti-psgl-1 antibodies and methods of identification and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2011524858A JP2011524858A (ja) | 2011-09-08 |
| JP2011524858A5 true JP2011524858A5 (cg-RX-API-DMAC7.html) | 2012-05-10 |
Family
ID=41316376
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011509761A Pending JP2011524858A (ja) | 2008-05-15 | 2009-05-15 | 抗ｐｓｇｌ−１抗体並びにその同定及び使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US7833530B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP2291536A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2011524858A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2009246166B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2724415C (cg-RX-API-DMAC7.html) |
| WO (1) | WO2009140623A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8945565B2 (en) | 2006-12-01 | 2015-02-03 | Selexys Pharmaceuticals Corporation | Methods of treating inflammatory or thrombotic conditions with anti-P-selectin antibodies |
| PT2662091T (pt) | 2006-12-01 | 2018-12-03 | Novartis Ag | Anticorpos anti-p-selectina e métodos para os utilizar no tratamento de doenças inflamatórias |
| WO2012088265A1 (en) * | 2010-12-21 | 2012-06-28 | Selexys Pharmaceuticals Corporation | Anti-p-selectin antibodies and methods of their use and identification |
| BR112013031892A2 (pt) * | 2011-06-13 | 2016-11-22 | Abgenomics Cooperatief Ua | anticorpos anti-psgl-1 e seu uso |
| JP6236255B2 (ja) * | 2012-08-31 | 2017-11-22 | 旭化成メディカル株式会社 | 基材及びデバイス |
| WO2018132476A1 (en) | 2017-01-11 | 2018-07-19 | Bristol-Myers Squibb Company | Psgl-1 antagonists and uses thereof |
| KR20240151866A (ko) | 2017-03-14 | 2024-10-18 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
| EP3619299A1 (en) * | 2017-05-03 | 2020-03-11 | BioMarin Pharmaceutical Inc. | Improved lentiviruses for transduction of hematopoietic stem cells. |
| JP7510879B2 (ja) | 2018-03-21 | 2024-07-04 | ファイヴ プライム セラピューティクス インク | 酸性ｐＨでＶＩＳＴＡに結合する抗体 |
| TW202023629A (zh) * | 2018-06-29 | 2020-07-01 | 美商維西歐製藥公司 | 用於調節單核球及巨噬細胞發炎表型之組合物及方法以及其免疫療法用途 |
| KR20210031722A (ko) | 2018-07-11 | 2021-03-22 | 파이브 프라임 테라퓨틱스, 인크. | 산성 pH에서 VISTA에 결합하는 항체 |
| MX2021000786A (es) | 2018-07-20 | 2021-06-15 | Pf Medicament | Receptor para supresor de ig del dominio v de activación de células t (vista). |
| WO2020247371A1 (en) * | 2019-06-04 | 2020-12-10 | Verseau Therapeutics, Inc. | Anti-psgl-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof |
| KR102242285B1 (ko) * | 2019-10-02 | 2021-04-20 | 코아스템(주) | 중간엽줄기세포의 전신홍반루푸스 치료효과 예측용 바이오마커 조성물 |
| CN113322223B (zh) * | 2021-06-03 | 2023-09-12 | 重庆市畜牧科学院 | 富硒酵母基因工程菌及其表面展示系统及其构建方法 |
| CN113667015B (zh) * | 2021-08-20 | 2022-10-11 | 北京康特泊瑞生物医药科技股份公司 | 靶向psgl-1蛋白的抗体及其用途 |
| KR20250094658A (ko) * | 2022-09-13 | 2025-06-25 | 테더렉스 파마슈티컬스 코포레이션 | 항체, 조성물 및 치료 방법 |
| WO2025191538A1 (en) * | 2024-03-14 | 2025-09-18 | Tetherex Pharmaceuticals Corporation | Pharmaceutical compositions and methods of treatment |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7016A (en) * | 1850-01-15 | Mill for grinding | ||
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4036945A (en) | 1976-05-03 | 1977-07-19 | The Massachusetts General Hospital | Composition and method for determining the size and location of myocardial infarcts |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4331647A (en) | 1980-03-03 | 1982-05-25 | Goldenberg Milton David | Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers |
| JPS5896026A (ja) | 1981-10-30 | 1983-06-07 | Nippon Chemiphar Co Ltd | 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
| US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
| DK122686D0 (da) | 1986-03-17 | 1986-03-17 | Novo Industri As | Fremstilling af proteiner |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| DE3883899T3 (de) | 1987-03-18 | 1999-04-22 | Sb2, Inc., Danville, Calif. | Geänderte antikörper. |
| US5667988A (en) * | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US6277975B1 (en) * | 1992-10-23 | 2001-08-21 | Genetics Institute, Inc. | Fusions of P-selectin ligand protein and polynucleotides encoding same |
| US6551795B1 (en) * | 1998-02-18 | 2003-04-22 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics |
| US7223845B2 (en) | 1998-06-16 | 2007-05-29 | The Board Of Regents Of The University Of Oklahoma | Synthetic glycosulfopeptides and methods of synthesis thereof |
| US20090087878A9 (en) * | 1999-05-06 | 2009-04-02 | La Rosa Thomas J | Nucleic acid molecules associated with plants |
| US7605238B2 (en) * | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
| ATE321570T1 (de) * | 2000-05-19 | 2006-04-15 | Blood Res Center | Verfahren zur behandlung von hämostatischen störungen durch lösliches p-selectin |
| US20040002450A1 (en) * | 2000-12-29 | 2004-01-01 | Janette Lazarovits | Y17 - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US20040001839A1 (en) * | 2000-12-29 | 2004-01-01 | Avigdor Levanon | Multimers - isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof |
| US7744888B2 (en) * | 2001-08-03 | 2010-06-29 | Abgenomics Cooperatief U.A. | Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies |
| WO2003088980A1 (en) * | 2002-04-18 | 2003-10-30 | Embury Stephen H | Method and composition for preventing pain in sickle cell patients |
| US20070041972A1 (en) * | 2003-05-30 | 2007-02-22 | Alexion Pharmaceuticals, Inc. | Antibodies and fusion proteins that include engineered constant regions |
| US20050069955A1 (en) * | 2003-06-30 | 2005-03-31 | Daniel Plaksin | Antibodies and uses thereof |
| WO2006124269A2 (en) * | 2005-05-16 | 2006-11-23 | Amgen Fremont Inc. | Human monoclonal antibodies that bind to very late antigen-1 for the treatment of inflammation and other disorders |
| WO2007067984A2 (en) * | 2005-12-09 | 2007-06-14 | Wyeth | Neutralizing antibodies against primate psgl-1 and uses therefor |
| US20070298034A9 (en) * | 2005-12-09 | 2007-12-27 | Angela Widom | Sulfotyrosine specific antibodies and uses therefor |
| WO2007143711A2 (en) * | 2006-06-07 | 2007-12-13 | Wisconsin Alumni Research Foundation | Blood-brain barrier targeting antibodies |
-
2009
- 2009-05-15 JP JP2011509761A patent/JP2011524858A/ja active Pending
- 2009-05-15 EP EP09747704A patent/EP2291536A4/en not_active Ceased
- 2009-05-15 WO PCT/US2009/044188 patent/WO2009140623A2/en not_active Ceased
- 2009-05-15 AU AU2009246166A patent/AU2009246166B2/en active Active
- 2009-05-15 US US12/467,060 patent/US7833530B2/en active Active
- 2009-05-15 EP EP18154983.3A patent/EP3388527A1/en active Pending
- 2009-05-15 CA CA2724415A patent/CA2724415C/en active Active
-
2010
- 2010-11-15 US US12/946,372 patent/US20110081666A1/en not_active Abandoned